Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that the company will present preclinical data highlighting the CYP17 lyase inhibition profile of galeterone in prostate cancer models at the American Association for Cancer Research (AACR) Annual Meeting 2013 in Washington, D.C.
